About Conference
On behalf of the Vaccines Advisory Committee we take great pleasure in welcoming academic scientists, researchers, research scholars, students and experts of application fields for the Conference on "39th Euro Global Summit and Expo on Vaccines & Vaccination" to foster the advancement in the field by contributing with your expertise to what promises to be a very comprehensive and exciting meeting in the fascinating location of UK.
Conference Highlights
A vaccine is an inactivated form of bacteria or virus that is injected into the body to simulate an actual infection. Because the injected microorganisms are 'dead,' they don't cause a person to become sick. Instead, vaccines stimulate an immune response by
the body that will fight off that type of illness. It covers infectious
disease targets and non-infectious disease targets. To generate
vaccine-mediated protection is a complex challenge. Currently available
vaccines have largely been developed empirically, with little or no
understanding on how they activate the immune system.
Their early protective efficacy is primarily conferred by the induction
of antigen-specific antibodies. However, there is more to
antibody-mediated protection than the peak of vaccine-induced antibody
titers.
Related Societies:
Europe:
European Society for Paediatric Infectious Diseases; European Union Geriatric Medicine Society; European Federation of Immunological Societies; European Academy of Allergy and Clinical Immunology; Royal Society of London; Epidemiological Society of London; Edward Jenner Society
USA:
The Anti-Vaccination Society of America; Infectious Diseases Society of America; Association of Immunization Managers; Clinical Immunology Society
Asia and Middle-East:
Japanese Society for Immunology; Singaporean Society for Immunology; Australasian Society of Clinical Immunology and Allergy
Track 2: Vaccine Research & Development
Vaccine Development is
an activity that focuses on a variety of technological initiatives and
applied research, which enhance and promote improved systems and
practices for vaccine safety. In the past year, the unprecedented Ebola disease outbreak
galvanized research and industry response and as we continue to search
for solutions, we must review the lessons learned in order to overcome
the current challenges. Vaccines development is a long, complex process,
often lasting 10-15 years and involving a combination of public and
private involvement. The current system for developing, testing, and
regulating vaccines developed during the 20th century as the groups
involved standardized their procedures and regulations.
Related Societies:
Europe:
European Academy of Paediatrics; European Malaria Foundation (e-malaria Foundation); European Malaria Vaccine Development (EUROMALVAC); European malaria Vaccine Initiative (EMVI)
USA:
Autism Science Foundation (ASF); Childhood Influenza Immunization Coalition (CIIC); Edward Jenner Vaccine Society; Global Polio Eradication Initiative
Asia and Middle-East:
Lebanese Society of Allergy and Immunology; Moldavian Society of Allergology & Immunology; Moroccan Society of Allergology and Clinical Immunology
Drug delivery systems are engineered technologies for the targeted delivery and/or controlled release of therapeutic agents.
Drugs have long been used to improve health and extend lives. The
practice of drug delivery has changed dramatically in the last few
decades and even greater changes are anticipated in the near future.
Biomedical engineers have not only contributed substantially to our
understanding of the physiological barriers to efficient drug
delivery—such as transport in the circulatory system and drug movement
through cells and tissues—they have contributed to the development of a
number of new modes of drug delivery that have entered clinical
practice. Role of vaccine delivery technologies includes rational
development of vaccines, achieving immunization goals, supporting best clinical practice.
Vaccines continue to revolutionize our ability to prevent disease and
improve health. With every technological advance, we are able to extend
the benefits of vaccines to more people and provide better protection
from life-threatening infectious diseases.
Related Societies:
Europe:
European Society for Immunodeficiency; French Society of Immunology; Immunology of Diabetes Society; Deutsche Gesellschaft für Immunologie
USA:
American Academy of Paediatrics (AAP); American College Health Association (ACHA); Association of Immunization Managers (AIM); Association for Professionals in Infection Control and Epidemiology (APIC)
Asia and Middle-East:
Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAPARI); Asia Pacific Association of Pediatric Allergy, Respirology and Immunology (APAPARI); Commonwealth of Independent States Society of Allergology and Immunology (CIS Society)
Track 4: Vaccines Safety & Efficacy
Vaccines are the best defense we have against serious, preventable, and sometimes deadly contagious diseases. Vaccines are some of the safest medical products available, but like any other medical product, there may be health risk. Accurate information about the value of vaccines as well as their possible side-effects helps
people to make informed decisions about vaccination. The safety of
vaccines is carefully monitored, starting early in the product
development and continuing for as long as the vaccine is being used.
Find out about what is done before and after vaccines are approved for
use and what is known about the benefits and safety of specific
vaccines. There is a lot of false information about vaccines safety on
the Internet. This can be confusing. Discover the answers to common
questions and concerns about vaccines.
Related Societies:
Europe:
Croatian Society of Allergology and Clinical Immunology; Czech Society of Allergology and Clinical Immunology; Finnish Society of Allergology and Clinical Immunology; French Society of Allergology and Clinical Immunology
USA:
Panamanian Association of Allergology and Clinical Immunology; Paraguayan Society of Allergy, Asthma, and Immunology; Peruvian Society of Allergy and Immunology; Venezuelan Society of Allergy, Asthma and Immunology
Asia and Middle-East:
Philippine Society of Allergy, Asthma and Immunology; Taiwan Academy of Pediatric Allergy Asthma Immunology; Vietnam Association of Allergy, Asthma and Clinical Immunology
Track 5: Vaccines Business Development
Collaboration plays a major part in the success of Vaccines Business.
This is exemplified in the relationships built, products launched and
lives improved.
Vaccines Business development:
comprise a number of tasks and processes generally aiming at developing
and implementing growth opportunities within and between organizations.
It is a subset of the fields of business, commerce and organizational
theory. Vaccine development programs face several challenges that set them apart from other types of healthcare product development programs.
Related Societies:
Europe:
Croatian Society of Allergology and Clinical Immunology; Czech Society of Allergology and Clinical Immunology; Finnish Society of Allergology and Clinical Immunology; French Society of Allergology and Clinical Immunology
USA:
Panamanian Association of Allergology and Clinical Immunology; Paraguayan Society of Allergy, Asthma, and Immunology; Peruvian Society of Allergy and Immunology; Venezuelan Society of Allergy, Asthma and Immunology
Asia and Middle-East:
Philippine Society of Allergy, Asthma and Immunology; Taiwan Academy of Pediatric Allergy Asthma Immunology; Vietnam Association of Allergy, Asthma and Clinical Immunology
Track 6: Vaccine Adjuvants
Vaccine adjuvants –
is an ingredient of a vaccine that helps create a stronger immune
response in the patient’s body. In other words, adjuvants help vaccines
work better. Some vaccines made from weakened or dead germs contain
naturally occurring adjuvants and help the body produce a strong
protective immune response.
However, most vaccines developed today include just small components of
germs, such as their proteins, rather than the entire virus or
bacteria. These vaccines often must be made with adjuvants to ensure the
body produces an immune response strong enough to protect the patient
from the germ he or she is being vaccinated against. Aluminum gels or
aluminum salts are vaccines ingredients that have been used in vaccines
since the 1930s. Small amounts of aluminum are added to help the body
build stronger immunity against
the germ in the vaccine. Aluminum is one of the most common metals
found in nature and is present in air, food, and water. The amount of
aluminum present in vaccines is low and is regulated by the U.S. Food
and Drug Administration (FDA).
Related Societies:
Europe:
European Society for Immunodeficiency; French Society of Immunology; Immunology of Diabetes Society; Deutsche Gesellschaft für Immunologie; Royal Society of London; Epidemiological Society of London; Edward Jenner Society
USA:
American Academy of Paediatrics (AAP); American College Health Association (ACHA); Association of Immunization Managers (AIM); Association for Professionals in Infection Control and Epidemiology (APIC)
Asia and Middle-East:
Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAPARI); Asia Pacific Association of Pediatric Allergy, Respirology and Immunology (APAPARI); Commonwealth of Independent States Society of Allergology and Immunology (CIS Society)
Track 7: HIV/AIDS Vaccines
An AIDS vaccine
does not yet exist, but efforts to develop a vaccine against HIV, the
virus that causes AIDS, have been underway for many years. An HIV
vaccine could be effective in either of two ways. A “preventive” vaccine
would stop HIV infection occurring
altogether, whereas a “therapeutic” vaccine would not stop infection,
but would prevent or delay illness in people who do become infected, and
might also reduce the risk of them transmitting the virus to other
people. Although a preventive vaccine would be ideal, therapeutic
vaccines would also be highly beneficial. The basic idea behind all HIV vaccines is to encourage the human immune system to fight HIV.
Related Societies:
Europe:
European Society for Immunodeficiency; French Society of Immunology; Immunology of Diabetes Society; Deutsche Gesellschaft für Immunologie
USA:
American Academy of Paediatrics (AAP); American College Health Association (ACHA); Association of Immunization Managers (AIM); Association for Professionals in Infection Control and Epidemiology (APIC)
Asia and Middle-East:
Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAPARI); Asia Pacific Association of Pediatric Allergy, Respirology and Immunology (APAPARI); Commonwealth of Independent States Society of Allergology and Immunology (CIS Society)
Track 8: Immunology/Animal Models
Observations in animal models have substantially advanced our knowledge of immune system adaptation, changes during the aging process, and age-associated degenerative diseases with autoimmune characteristics.
Animal models provided early proof that discrimination of self (that
which the immune system identifies as belonging to the body) and
non-self (that which the immune system identifies as foreign to the
body) is determined not entirely at conception, but, to a large extent,
during early fetal development by a process called immune adaptation.
The animal experiments confirmed the premise that immune adaptation is
determined by the fetal or neonatal environment, rather than inherited.
Animal models have substantially enhanced our understanding of the role
of the immune system in tissue physiology and pathology.
The knowledge gained from animal models offers hope for future
modification of the human immune system to combat a number of disease
processes.
Related Societies:
Europe:
British Society for Immunology; Microbiology Society, London; Royal Society of London; Epidemiological Society of London; Edward Jenner Society; Society for Applied Microbiology; European Society of Clinical Microbiology and Infectious Diseases
USA:
The Federation of Clinical Immunology Societies; The American Association of Immunologists; American Society for Microbiology; Colombian Allergy, Asthma and Immunology Association; Canadian Society for Immunology
Asia and Middle-East:
Indian society of Allergy, Asthma and Clinical Immunology; Australasian Society of Clinical Immunology and Allergy; Bangladesh Society of Allergy and Immunology
Vaccination given to children is called children Immunization.
It is currently recommended that all children receive vaccination
against the infectious diseases unless the child has special
circumstances, such as a compromised immune system or neurological disorders.
In our mobile society, over a million people each day people travel to
and from other countries, where many vaccine-preventable diseases remain
relatively common. Without vaccines, epidemics of many preventable
diseases could return, resulting in increased - and unnecessary -
illness, disability, and death among children.
We have record or near record low levels of vaccine-preventable
childhood diseases in the United States, but that does not mean these
have disappeared. Many of the viruses and bacteria are still circulating
in this country or are only a plane ride away. That’s why it’s
important that children, especially infants and young children receive
recommended immunizations on time.
Vaccines can help keep you and your growing family healthy. If you are pregnant or planning a pregnancy,
the specific vaccinations you need are determined by factors such as
your age, lifestyle, medical conditions you may have, such as asthma or
diabetes, type and locations of travel, and previous vaccinations.
Benefits of vaccinating pregnant women usually outweigh potential risks
when the likelihood of disease exposure is high, when infection would
pose a risk to the mother or fetus, and when the vaccine is unlikely to
cause harm. All women who will be pregnant (any trimester) during the
flu season should be offered this vaccine. Talk to your doctor to see if
this applies to you. Tetanus/Diphtheria/Pertussis (Tdap):
Tdap is recommended during pregnancy, preferably between 27 and 36
weeks' gestation, to protect baby from whooping cough.
Related Societies:
Europe:
European Academy of Paediatrics; European Malaria Foundation (e-malaria Foundation); European Malaria Vaccine Development (EUROMALVAC); European malaria Vaccine Initiative (EMVI)
USA:
Autism Science Foundation (ASF); Childhood Influenza Immunization Coalition (CIIC); Edward Jenner Vaccine Society; Global Polio Eradication Initiative
Asia and Middle-East:
Lebanese Society of Allergy and Immunology; Moldavian Society of Allergology & Immunology; Moroccan Society of Allergology and Clinical Immunology
Track 10: Human Preventive & Therapeutic Vaccines
A preventative vaccine is
administered to a person who is free of the targeted infection. By
introducing a part of the virus or an inactive virus (which acts like a
decoy) into the body, the immune system reacts by producing antibodies.
Preventive vaccines are widely used to prevent diseases like polio, chicken pox, measles, mumps, rubella, influenza (flu), and hepatitis A and B.
In addition to preventive vaccines, there are also “therapeutic
vaccines”. These are vaccines that are designed to treat people who
already have a disease. Some scientists prefer to refer to therapeutic
vaccines as “therapeutic immunogens.
Related Societies:
Europe:
Swiss Society for Microbiology; Federation of European Microbiological Societies; International Society of Vaccines; International Union of Immunological Society; Royal Society of London; Epidemiological Society of London; Edward Jenner Society
USA:
Ecuadorian Society of Allergy, Asthma, and Immunology; Guatemalan Allergy, Asthma and Clinical Immunology Association; Honduran Society of Allergy and Clincial Immunology
Asia and Middle-East:
Indonesian Society of Allergy and Immunology; Korean Academy of Asthma, Allergy and Clinical Immunology; Malaysian Society of Allergy and Immunology
Track 11: Cancer Vaccines and Immunotherapy
Immunotherapeutics is
treatment that uses your body's own immune system to help fight cancer.
Get information about the different types of immunotherapy and the
types of cancer they are used to treat. The main types of immunotherapy
now being used to treat cancer include:
- Cancer vaccines
- Monoclonal antibodies
- Immune checkpoint inhibitors
- Other, non-specific immunotherapies
Some types of immunotherapy are also sometimes called biologic therapy or biotherapy.
In the last few decades immunotherapy has become an important part of
treating some types of cancer. Newer types of immune treatments are now
being studied, and they’ll impact how we treat cancer in the future.
Immunotherapy includes treatments that work in different ways. Some
boost the body’s immune system in a very general way. Others help train
the immune system to attack cancer cells specifically. Immunotherapy
works better for some types of cancer than for others. It’s used by
itself for some of these cancers, but for others it seems to work better
when used with other types of treatment.
Related Societies:
Europe:
European Academy of Paediatrics; European Malaria Foundation (e-malaria Foundation); European Malaria Vaccine Development (EUROMALVAC); European malaria Vaccine Initiative (EMVI)
USA:
Autism Science Foundation (ASF); Childhood Influenza Immunization Coalition (CIIC); Edward Jenner Vaccine Society; Global Polio Eradication Initiative
Asia and Middle-East:
Lebanese Society of Allergy and Immunology; Moldavian Society of Allergology & Immunology; Moroccan Society of Allergology and Clinical Immunology
Track 12: Vaccines for Vector-borne Diseases
Vaccines that target blood-feeding disease vectors, such as mosquitoes
and ticks, have the potential to protect against the many diseases
caused by vector-borne pathogens. Vector-borne diseases are
among the most complex of all infectious diseases to prevent and
control. Vector- borne diseases, most of which are transmitted in and
around the home, are best controlled by a combination of vector control
(use of public health insecticides on bednets, or by spraying),
medicines and vaccines.
Historically, successful vector-borne disease prevention resulted from management or elimination of vector populations. Malaria was
driven out of the USA and most of Europe in this way. Where vector
control has been consistently applied in the past, the results have been
dramatic, especially with early efforts to control malaria by spraying
the inside surfaces of houses with insecticides. Indoor Residual
Spraying (IRS) and long-lasting insecticide treated bednets have been
very effective over the last 10 years and are widely regarded as one of
the main contributors to the more than 1 million lives saved.
In contrast to expenditure and effort on medicine, diagnostic and vaccine development,
relatively little attention was given to vector control in the past.
The foresighted establishment of IVCC in 2005, with a grant from the
Bill and Melinda Gates Foundation began the process of bringing Vector
Control into the mainstream strategy for future eradication of malaria
and other vector-borne diseases.
Related Societies:
Europe:
European Academy of Allergy and Clinical Immunology (EAACI); European Molecular Biology Laboratory (EMBL); Medical Research Council (MRC); Royal Society of London; Epidemiological Society of London; Edward Jenner Society
USA:
Hepatitis B Foundation (HBF); Infectious Diseases Society of America (IDSA); National Adult and Influenza Immunization Summit (NAIIS); National Foundation for Infectious Diseases (NFID); Paediatrics Infectious Diseases Society (PIDS)
Asia and Middle-East:
Russian Association of Allergology and Clinical Immunology; Turkish National Society of Allergy and Clinical Immunology; Ukrainian Association of Allergologists and Clinical Immunologists
Track 13: Vaccines for Older Adults
Vaccines are an important part of routine preventive care for older
adults, but most adults don’t get their vaccines as recommended.
Omitting vaccination leaves
adults needlessly vulnerable to severe illnesses, long-term suffering
and death from preventable infections. Vaccines are recommended for
adults of all ages, they are particularly important for older persons
who are at great risk of serious debilitating consequences and death
from infectious diseases.
Vaccination is particularly important for individuals living in nursing
homes or assisted living facilities, as disease can spread easily among
people in close proximity.
Related Societies:
Europe:
British Society for Allergy and Clinical Immunology; British Society for Histocompatibility and Immunogenetics; European Federation of Immunological Societies; European Academy of Allergology and Clinical Immunology
USA:
Voices for Vaccines (VFV); National Institute of Allergy and Infectious Disease (NIAID); American Public Health Association (APHA); American Association for the Advancement of Science (AAAS); American Society for Microbiology (ASM)
Asia and Middle-East:
Australasian Society for Immunology; Australasian Society of Clinical Immunology and Allergy; Israel Association of Allergy and Clinical Immunology; Jordanian Society for Allergy and Clinical Immunology; Japanese Society for Immunology
Track 14: Veterinary Vaccines
Veterinary vaccines are to improve the health and welfare of companion animals, increase production of livestock in a cost-effective manner, and prevent animal-to-human transmission from both domestic animals and wildlife.
Several vaccine types can de distinguished among the second-generation
veterinary vaccines, depending whether they are live or inactivated,
according to the strain of rabies virus used and the characteristics of
the cell substrate chosen for viral replication. More recently a third
generation of live veterinary rabies vaccine has been developed using
recombinant technology. Depending upon the expression system these
vaccines are used either parenterally or orally. Oral rabies vaccines are widely used in foxes in Europe and in racoons in the USA.
Related Societies:
Europe:
European Academy of Allergy and Clinical Immunology (EAACI); European Molecular Biology Laboratory (EMBL); Medical Research Council (MRC)
USA:
Hepatitis B Foundation (HBF); Infectious Diseases Society of America (IDSA); National Adult and Influenza Immunization Summit (NAIIS); National Foundation for Infectious Diseases (NFID); Paediatrics Infectious Diseases Society (PIDS)
Asia and Middle-East:
Russian Association of Allergology and Clinical Immunology; Turkish National Society of Allergy and Clinical Immunology; Ukrainian Association of Allergologists and Clinical Immunologists
Most vaccines against viral infection are
effective at preventing disease. However, they are not 100% effective
for a number of reasons, reactions can occur after vaccinations.
It is difficult for many of us today to appreciate the dangers of childhood viral infections.
Most of the vaccines in use against viruses are very effective at preventing disease. However, for a variety of reasons, they can fail:
- The vaccine becomes inactive due to incorrect storage, if used past its expiry date, or if incorrectly administered.
- Individuals unpredictably fail to produce an adequate immune response to the vaccine.
- Vaccine immunity “fades” over time.
The different vaccine combinations at each time point do not interfere
with one another and there is no increased risk of serious side-effects
when they are given at the same time.
Bacterial vaccines contain killed or attenuated bacteria that activate
the immune system. Antibodies are built against that particular
bacteria, and prevents bacterial infection later.
Most vaccines against bacterial infections are effective at preventing
disease, reactions can occur after vaccinations. Vaccines are available
against tuberculosis, diphtheria, tetanus, pertussis, Haemophilus influenzae type B, cholera, typhoid, and Streptococcus pneumoniae.
Related Societies:
Europe:
European Society for Paediatric Infectious Diseases; European Union Geriatric Medicine Society; European Federation of Immunological Societies; European Academy of Allergy and Clinical Immunology
USA:
The Anti-Vaccination Society of America; Royal Society of London; Epidemiological Society of London; Edward Jenner Society; Infectious Diseases Society of America; Association of Immunization Managers; Clinical Immunology Society
Asia and Middle-East:
Japanese Society for Immunology; Singaporean Society for Immunology; Australasian Society of Clinical Immunology and Allergy
Track 16: Vaccines for Respiratory Diseases
Population protection by vaccination against infections has been one of the major achievements of public health and is of considerable importance in controlling respiratory diseases.
Related Societies:
Europe:
British Society for Allergy and Clinical Immunology; British Society for Histocompatibility and Immunogenetics; European Federation of Immunological Societies; European Academy of Allergology and Clinical Immunology
USA:
Voices for Vaccines (VFV); National Institute of Allergy and Infectious Disease (NIAID); American Public Health Association (APHA); American Association for the Advancement of Science (AAAS); American Society for Microbiology (ASM)
Asia and Middle-East:
Australasian Society for Immunology; Australasian Society of Clinical Immunology and Allergy; Israel Association of Allergy and Clinical Immunology; Jordanian Society for Allergy and Clinical Immunology; Japanese Society for Immunology
Track 17: DNA Vaccines
DNA vaccination is
a technique for protecting an animal against disease by injecting it
with genetically engineered DNA so cells directly produce an antigen,
resulting in a protective immunological response.
Vaccination consists
of stimulating the immune system with an infectious agent, or
components of an infectious agent, modified in such a manner that no
harm or disease is caused, but ensuring that when the host is confronted
with that infectious agent, the immune system can adequately neutralize
it before it causes any ill effect. For over a hundred years
vaccination has been effected by one of two approaches: either
introducing specific antigens against which the immune system reacts
directly; or introducing live attenuated infectious agents that
replicate within the host without causing disease synthesize the
antigens that subsequently prime the immune system.
The field of DNA vaccination is developing rapidly. Vaccines currently
being developed use not only DNA, but also include adjuncts that assist
DNA to enter cells, target it towards specific cells, or that may act as
adjuvants in stimulating or directing the immune response.
Ultimately, the distinction between a sophisticated DNA vaccine and a
simple viral vector may not be clear. Many aspects of the immune
response generated by DNA vaccines are not understood. However, this has
not impeded significant progress towards the use of this type of
vaccine in humans, and clinical trials have begun.
Related Societies:
Europe:
Albanian Society of Allergology and Clinical Immunology; Austrian Society of Allergology and Immunology; Belgian Society of Allergy and Clinical Immunology; British Society of Allergy and Clinical Immunology; Royal Society of London; Epidemiological Society of London; Edward Jenner Society
USA:
Argentine Association of Allergy and Immunology; Argentine Society of Allergy and Immunology; Brazilian Society of Allergy and Immunology; Chilean Society of Allergy and Immunology
Asia and Middle-East:
Allergy & Immunology Society of Sri Lanka; Allergy and Clinical Immunology Society of Singapore; Allergy and Immunology Society of Thailand
Track 18: Hepatitis Vaccines
Hepatitis is
an inflammation of the liver. The condition can be self-limiting or can
progress to fibrosis (scarring), cirrhosis or liver cancer. Hepatitis
viruses are the most common cause of hepatitis in the world but other
infections, toxic substances (e.g. alcohol, certain drugs), and
autoimmune diseases can also cause hepatitis.
There are 5 main hepatitis viruses,
referred to as types A, B, C, D and E. These 5 types are of greatest
concern because of the burden of illness and death they cause and the
potential for outbreaks and epidemic spread. In particular, types B and C
lead to chronic disease in hundreds of millions of people and,
together, are the most common cause of liver cirrhosis and cancer.
Hepatitis A and E are typically caused by ingestion of contaminated
food or water. Hepatitis B, C and D usually occur as a result of
parenteral contact with infected body fluids. Common modes of
transmission for these viruses include receipt of contaminated blood or
blood products, invasive medical procedures using contaminated equipment
and for hepatitis B transmission from mother to baby at birth, from
family member to child, and also by sexual contact.
Acute infection may occur with limited or no symptoms, or may include symptoms such as jaundice (yellowing of the skin and eyes), dark urine, extreme fatigue, nausea, vomiting and abdominal pain.
Related Societies:
Europe:
British Society for Immunology; Microbiology Society, London; Society for Applied Microbiology; European Society of Clinical Microbiology and Infectious Diseases
USA:
The Federation of Clinical Immunology Societies; The American Association of Immunologists; American Society for Microbiology; Colombian Allergy, Asthma and Immunology Association; Canadian Society for Immunology
Asia and Middle-East:
Indian society of Allergy, Asthma and Clinical Immunology; Australasian Society of Clinical Immunology and Allergy; Bangladesh Society of Allergy and Immunology
Track 19: Mucosal Vaccines
Most infectious agents enter
the body at mucosal surfaces and therefore mucosal immune responses
function as a first line of defence. Protective mucosal immune responses
are most effectively induced by mucosal immunization through oral,
nasal, rectal or vaginal routes, but the vast majority of vaccines in
use today are administered by injection. Immunisation involves the
delivery of antigens to the mucosal immune system (dispersed or organised into units such as Peyer’s patches in the intestine or the nasal-associated lymphoid tissue in
the oropharangeal cavity). The antigen delivery systems may comprise a
simple buffer solution with/without adjuvants or an advanced particulate
formulation, such as liposomes or nanoparticles. The most commonly
evaluated route for mucosal antigen delivery is oral, but other routes
have also been explored.
Related Societies:
Europe:
Swiss Society for Microbiology; Federation of European Microbiological Societies; International Society of Vaccines; Royal Society of London; Epidemiological Society of London; Edward Jenner Society; International Union of Immunological Society
USA:
Ecuadorian Society of Allergy, Asthma, and Immunology; Guatemalan Allergy, Asthma and Clinical Immunology Association; Honduran Society of Allergy and Clincial Immunology
Asia and Middle-East:
Special Issues
All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.
Abstracts will be provided with Digital Object Identifier by Cross ref
See more : https://europe.vaccineconferences.com/